Trial Profile
A Phase 1, Open-Label Safety, Pharmacokinetic and Efficacy Study of TAS4464 in Patients With Multiple Myeloma or Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2021
Price :
$35
*
At a glance
- Drugs TAS 4464 (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Oncology
- 07 Mar 2018 Status changed from recruiting to discontinued.
- 01 May 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2016 New trial record